Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | MYOF | CTRPv2 | pan-cancer | AAC | -0.26 | 5e-12 |
mRNA | ANXA5 | CTRPv2 | pan-cancer | AAC | -0.24 | 6e-08 |
mRNA | RTFDC1 | CTRPv2 | pan-cancer | AAC | -0.23 | 3e-11 |
mRNA | TNFRSF12A | CTRPv2 | pan-cancer | AAC | -0.22 | 4e-08 |
mRNA | LTBR | CTRPv2 | pan-cancer | AAC | -0.21 | 2e-07 |
mRNA | RNF181 | CTRPv2 | pan-cancer | AAC | -0.21 | 1e-10 |
mRNA | TPD52L2 | CTRPv2 | pan-cancer | AAC | -0.21 | 2e-09 |
mRNA | MANBAL | CTRPv2 | pan-cancer | AAC | -0.21 | 8e-07 |
mRNA | MCFD2 | CTRPv2 | pan-cancer | AAC | -0.21 | 2e-09 |
mRNA | FAM209A | CTRPv2 | pan-cancer | AAC | -0.2 | 2e-09 |